Scott D Connell

Title: Scott D. Connell: Innovator in Biopolymeric Array Technology

Introduction

Scott D. Connell, a distinguished inventor based in Saratoga, CA, has made significant contributions to the field of molecular analysis through his innovations in biopolymeric array technologies. With a total of three patents to his name, Connell's work focuses on advancing the capabilities of array scanners for both genomics and proteomics applications.

Latest Patents

Connell’s latest patents include biopolymeric array scanners that automatically select dye-specific scale factors for various dyes. This innovation allows for streamlined processing in assays by using a constant master scale factor, regardless of the dye involved. The scanner automatically reads the arrays based on user input regarding the dyes utilized, offering convenience and consistency in molecular analysis. Additionally, his method and system for extracting data from surface arrays involve sophisticated algorithms that determine feature coordinates to accurately extract signal intensity values from scanned images. These methods enhance data analysis and ensure accuracy in interpreting results from molecular arrays.

Career Highlights

Scott D. Connell currently works at Agilent Technologies, Inc., a leading company in the field of life sciences, chemical analysis, and diagnostics. His contributions significantly enhance the technological landscape of molecular analysis, making it more efficient and user-friendly.

Collaborations

Throughout his career, Connell has collaborated with esteemed colleagues, including Glenda Choate Delenstarr and Nicholas Michael Sampas. These partnerships facilitate the exchange of ideas and enhance scientific advancements in the area of molecular diagnostics and analysis.

Conclusion

Scott D. Connell's innovative approach to biopolymeric array scanning technology exemplifies the impact inventors can have on scientific research and application. His contributions not only advance the technology in his field but also pave the way for future developments in molecular biology. As he continues to work at Agilent Technologies, Connell’s innovations hold great promise for the future of genomics and proteomics.